1McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59(17): 4291-4296.
3Rubin MA, Gerstein A, Reid K, et al. 10q23.3 Loss of heterozygosity is higher in lymph node-positive(pT2-3,N+)versus lymph node-negative(pT2-3, NO)prostate cancer. Hum Pathol 2000; 31(4): 504-508.
4Davies MA, Kim S J, Parikh NU, et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Cancer Res 2002; 8(6): 1904-1914.
5Drexler HCA, Pebler S. Inducible P27(kipl)expression inhibits proliferation of K 562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ 2003; 10(3): 290-301.
6Yang HY, Shao R, Hung MC, et al. p27 Kipl inhibits HER2/neu-mediated cell growth and tumorigenesis.Oncogene 2001; 20(28): 3695-3702.
7Cheng L, Lloyd RV, Veavear AL, et al. The cell cycle inhibitors p21(WAF1) and p27 (KIPI) are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000; 6(5):1896-1899.
8Chen Z, Fan Z, McNeal JE, et al. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 2003; 169(4): 1316-1319.
9Machtens S.Serth J,Bokemeyer C,et al.Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 2001; 95(5): 337-342.
10Yokoi S, Yasui K, Saito Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161(1): 207-216.
2Davies MA,Koul D, Dhesi H,et al. Regulation of AKT/PKB action, cellular growth, and apoptosis in prostate carcinomacells by MMAC/PTEN[J]. Cancer Res, 1999,59(11) :2551.
3Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC//PTEN and DMBT1 loci in gliomas:relationship to significance[J]. Clin Cancer Res, 1998,4(10) : 2447.
4Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive(pT2-3,N + ) versus lymph node-negative(pT2~3, N0) prostate cancer[J], Hum Pathol, 2000,31(4) : 504.
5Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression[J]. Proc Natl Acad Sci USA,1998,95(9):5246.
6Myers MP,Pass I ,Batty I H,et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function[J]. Proc Natl Acad Sci USA, 1998, 95 (23):13513.
7Davies MA, Kim SJ ,Parikh NU, et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells[J]. Clin Cancer Res, 2002,8 (6) : 1904.
8McMenumin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage[J]. Cancer Res, 1999,59(17):4291.
9Steck PA, Pershous MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, atchromosome 10q23.3 that is mutated in multiple advanced cancers[J]. Nat Genet, 1997,15(4) :356.
10Fleming ID,Cooper JS, Henson DE,et al. eds, American Joint Committee on Cancer, Manual for Staging of Cancer, 5th ed [M]. Lippincott Philadelphia, 1997: 220.
